New European Cancer Organisation Report Calls for Equitable Access to Precision Cancer Medicine Across Europe
核心洞察
Precision cancer medicine access in Europe remains heavily dependent on patient geography, with significant disparities in molecular testing and biomarker-driven therapies.
The European Cancer Organisation (搜索)'s new policy action report examines barriers to equitable access, data infrastructure gaps, and the role of real-world evidence.
Experts, policymakers, clinicians, and patient advocates contributed recommendations for making precision cancer medicine more accessible and sustainable across European health systems.
Precision cancer medicine is fundamentally reshaping oncology care across Europe, yet a patient's access to molecular testing, biomarker-driven therapies, and innovative diagnostics remains heavily dependent on where they live. This stark reality forms the core message of a new policy action report released by the European Cancer Organisation (搜索), which calls for urgent action to address widening disparities in cancer care across the continent.
The report brings together recommendations from a broad coalition of experts, policymakers, clinicians, researchers, and patient advocates, all working toward the shared goal of making precision cancer medicine more accessible and sustainable within European health systems.
Barriers to Equitable Access
The policy action report identifies multiple barriers that currently limit equitable access to precision cancer medicine across Europe. Chief among these is the geographic disparity in availability of molecular testing—a cornerstone of precision oncology that enables the identification of specific biomarkers and the matching of patients to targeted therapies. Without consistent access to such diagnostics, patients in underserved regions may be denied the benefits of biomarker-driven treatments that have become standard of care elsewhere.
The report also examines how fragmented data infrastructure and inconsistent utilization of real-world evidence hamper the ability to monitor outcomes, evaluate treatment effectiveness, and guide clinical decision-making across different healthcare settings.
The Role of Collaboration and Data Infrastructure
A central theme of the report is the critical importance of stronger collaboration between cancer centers. By fostering networks that share knowledge, standardize protocols, and pool resources, European health systems can begin to close the gap in precision medicine implementation. The report highlights how improved data infrastructure can support these collaborative efforts, enabling the collection and analysis of real-world evidence that informs both clinical practice and health policy.
Sustained Political and Financial Commitment
The European Cancer Organisation (搜索) underscores that progress in precision cancer medicine cannot be achieved without sustained EU-level political and financial support. The report argues that continued investment is essential not only for expanding access to existing diagnostics and therapies but also for building the infrastructure needed to support future innovations in cancer care.
The publication serves as both a diagnosis of current shortcomings and a roadmap for action, emphasizing that the promise of precision oncology will remain unfulfilled for many European patients unless systemic barriers are addressed through coordinated policy intervention.
A Broader Context of International Cooperation
The European Cancer Organisation (搜索)'s report emerges amid growing recognition that scientific collaboration across borders is essential to addressing global cancer challenges. In parallel discussions, such as those highlighted by the International Alliance for Personalised Medicine (IPM Alliance) during EU–MENA partnership events, experts have emphasized that collaboration is not a luxury but a necessity. Professor Adda Bounedjar, a prominent voice in these discussions, has stressed that building bridges between regions is fundamental to improving patient outcomes and ensuring that advances in cancer care reach more people, regardless of geography.
As cancer incidence continues to rise across regions, the convergence of policy action within Europe and collaborative frameworks extending beyond its borders reflects an increasingly shared understanding: the future of healthcare will be shaped by collective action, shared knowledge, and sustained investment in precision medicine.